Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrx loratadine approval

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Abbreviated New Drug Application for 10 mg loratadine orally disintegrating tablets, Andrx Corporation announces Nov. 4. The tablets are bioequivalent to Schering-Plough's Claritin RediTabs. Perrigo already markets Andrx's generic versions of Claritin D24 and Claritin RediTabs. Andrx is one of at least three companies facing suits filed by Schering-Plough arguing that the firms violated certain patent claims for Clarinex (desloratadine). A Washington, D.C. federal appeals court recently upheld a D.C. appeals court decision ruling that manufacturers of generic Claritin were not infringing on those claims (1"The Tan Sheet" Nov. 3, 2003, p. 4)...


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts